Ph3 Study of MK-5684 versus NHA in previously treated mCRPC

Phase III Clinical Trial

A Phase 3 Randomized Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (MK-5684-003)

Indication: Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer, Prostate Cancer
Trial Number: 06136624
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations